Advancing molecular medicine with new therapeutic compounds
The immune system is a fundamental element in the human body, as it prevents the body from becoming a host to pathogens or accumulating substances that could compromise the integrity of the organism. The immune system employs cascades of chemical and biological signals to help the body overcome adverse circumstances through a process known as inflammation. One of the most potent of these signals is the cytokine IL-1 beta, a factor that not only helps eliminate pathogens from the body but also, harmful aggregates of substances. Unfortunately, IL-1 beta secretion can become chronic and persistent over long periods of time, a process known as chronic inflammation. Significantly, unresolved chronic inflammation ultimately provokes a loss of tissue function, degeneration, fibrosis and cell death. In fact, chronic IL-1 beta activation is evident through the appearance of urate crystals in gout, cholesterol crystals in fatty liver disease, beta-amyloid plaques in Alzheimer’s disease or in the inhaled substances detected in the fibrotic lung. To address this challenge, Allinky is developing the first oral medicine against IL-1 beta-mediated chronic inflammation, in particular focusing on its use as a treatment for lung diseases such as IPF (Idiopathic pulmonary fibrosis), liver diseases such as NASH (Non-alcoholic steatohepatitis) and other IL-1b related pathologies.